by According to a research report “Injection Pen Market (By Product Type: Reusable and Disposable; By Therapy: Diabetes, Cancer, Osteoporosis, Autoimmune Diseases, Growth Hormone Therapy, Multiple Sclerosis, Fertility, Cardiovascular Diseases, Others; By End User: Hospitals & Diagnostic Centers and Homecare) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030″ published by Precedence Research.
The injection pen market value is projected to hit from USD 40.91 billion in 2022 to USD 79.3 billion by 2030, growing at a CAGR of 6.7% every year.
The study provides an analysis of the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2021 is considered as the base year.
The global injection pen market is significantly driven by several factors such as rising prevalence of various chronic diseases, technological advancements in the drug delivery devices, development of innovative drugs, and rising awareness regarding the availability of innovative drugs and drug delivery devices among the population.
The regulatory framework of the government regarding the approvals and reimbursement policies is playing a crucial role in the growth of the market. Moreover, the rising number of diabetic population and growing demand for the convenient and easy to use drug delivery solutions at homecare setting is fueling the demand for the injection pen market across the globe.
Get a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1497
Table of Contents
Scope of the Injection Pen Market
| Report Coverage | Details |
| Market Size in 2021 | USD 37.72 Billion |
| Growth Rate from 2021 to 2030 | 6.7% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Therapy, End User, Region |
Market Dynamics
Driver
Rapidly growing prevalence of chronic diseases
According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. This number is expected to rise by 47% from 2020 to 2040. According to the International Diabetes Federation, currently around 537 million people are living with diabetes and this number is expected to reach at 783 million by 2045.
Moreover, cardiovascular diseases accounts for 17.9 million of the global deaths and it is the leading cause of death across the globe. Therefore, the growing incidences of chronic diseases is expected to augment the demand for the injection pens across the globe.
Restraints
Availability of alternative drug delivery solutions
The growing number of needle stick injuries is compelling the consumers to opt for needle free drug delivery devices. Moreover, the rising preferences for the insulin pumps over insulin pens due to the growing needle stick anxiety may decrease the demand for the injection pens. This is a major factors that may hinder the growth of the global injection pen market during the forecast period.
Opportunity
Growing demand for the biosimilars
The development of various biosimilar drugs for the treatment of diseases such as diabetes, cancer, CVD, and autoimmune diseases is gaining rapid traction. The biosimilar drugs are expected to drive the growth of the injection pen market in the forthcoming years as the biosimilar drugs is expected to provide new growth aspects to the market players. Moreover, the regulatory authorities like EMA and FDA are actively participating in the clinical trials, product development, and approvals.
Challenge
Improper use may give rise to needle stick injuries
The lack of proper education and proper use of the injection pens may result in the overdose of the drugs and needle stick injuries to the patients. Moreover, there is a risk of getting affected by blood-borne diseases due to the injection pens. This poses a major threat to the injection pen market, as the aforementioned factors may result in the decline in the demand for the injection pens.
Read Also: Steam Turbine Market Value to Hit US$ 36.2 Bn by 2030 – Daily Tech Bulletin
Report Highlights
- Based on the product type, the disposable segment dominated the market in 2020. The more safety associated with the disposable needles and prevention of blood-borne diseases is the major factors that have driven the demand for the disposable injection pens across the globe.
- Based on the therapy, the diabetes segment dominated the injection pen market in 2020. The increased demand for the injection pens among the diabetic population for the regular maintenance of blood glucose levels has fostered the growth. The rising prevalence of diabetes is expected to further boost the growth of this segment. According to the International diabetes federation, the global diabetic population is estimated to reach at 783 million by 2045.
- Based on the end user, the homecare segment was the leading the market in 2020. The convenience and easy-to-use feature of the injection pens has enabled the patients to self-inject drugs without any medical assistance at home. This saves the cost for the patients.
Regional Snapshot
North America dominated the global injection pen market. The increased prevalence of non-communicable diseases among the US population is a significant driver of the market. Around 60% of the US population is suffering from one or more chronic diseases. The increased healthcare expenditure and easy availability of the injection pen has fostered the demand for the injection pen across North America. Moreover, the presence of geriatric population, who are more susceptible to various chronic diseases are resulting in the bolstering demand for the injection pens.
The increased adoption rate of the technologically advanced healthcare devices in the region coupled with the active participation of the government authorities in certifying the new drugs and drug delivery devices have contributed in the market growth.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. This can be attributed to the rising burden of chronic diseases among the population. According to the International Diabetes Federation, 3 in 4 diabetes affected people live in low and middle income countries.
Moreover, according to the United Nations, 80% of the global geriatric population will be living in the low and middle income countries by 2050. The rising disposable income, growing healthcare expenditure, rising awareness regarding the innovative drug delivery devices, and increasing investments in the development of advanced healthcare infrastructure are the major driving factors of the Asia Pacific injection pen market.
Some of the prominent players in the global injection pen market include:
- Eli Lilly
- Novo Nordisk
- Sanofi
- Merck
- AstraZeneca
- Ypsomed
- F.Hoffman-La Roche
- Becton Dickinson and Company
- Novartis
- Pfizer
- Haselmeier
- Owen Mumford
- WOCKHARDT
- Companion Medical
Segments Covered in the Report
By Product Type
- Reusable
- Disposable
By Therapy
- Diabetes
- Cancer
- Osteoporosis
- Autoimmune Diseases
- Growth Hormone Therapy
- Multiple Sclerosis
- Fertility
- Cardiovascular Diseases
- Others
By End User
- Hospitals & Diagnostic Centers
- Homecare
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Injection Pen Market
5.1. COVID-19 Landscape: Injection Pen Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Injection Pen Market, By Product
8.1. Injection Pen Market, by Product Type, 2021-2030
8.1.1. Reusable
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Disposable
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Injection Pen Market, By End User
9.1. Injection Pen Market, by End User, 2021-2030
9.1.1. Hospitals & Diagnostic Centers
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Homecare
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Injection Pen Market, By Therapy
10.1. Injection Pen Market, by Therapy, 2021-2030
10.1.1. Diabetes
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Cancer
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Osteoporosis
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Autoimmune Diseases
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Growth Hormone Therapy
10.1.5.1. Market Revenue and Forecast (2019-2030)
10.1.6. Multiple Sclerosis
10.1.6.1. Market Revenue and Forecast (2019-2030)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Injection Pen Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by End User (2019-2030)
11.1.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by End User (2019-2030)
11.2.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by End User (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by End User (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by End User (2019-2030)
11.3.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by End User (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by End User (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by End User (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by End User (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.4.2. Market Revenue and Forecast, by End User (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Therapy (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by End User (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Therapy (2019-2030)
Chapter 12. Company Profiles
12.1. Eli Lilly
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novo Nordisk
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sanofi
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Ypsomed
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F.Hoffman-La Roche
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Becton Dickinson and Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Haselmeier
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Owen Mumford
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. WOCKHARDT
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1497
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
